Dr. Vokes on Biomarker Selection in Head and Neck Cancer

Everett Vokes, MD
Published: Wednesday, Mar 22, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

PD-L1 is an imperfect selection factor, says Vokes, but it can enrich in patients who are likely to respond to immunotherapy. There is no clear cutoff between patients who will and patients who will not respond, though, calling for a more selective biomarker.
 


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

PD-L1 is an imperfect selection factor, says Vokes, but it can enrich in patients who are likely to respond to immunotherapy. There is no clear cutoff between patients who will and patients who will not respond, though, calling for a more selective biomarker.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x